First company to emerge from the AndzonBio Model of pipeline builders powered by AdBio Partners and Inserm Transfert, AndzonBio1 focuses on CardioVascular Renal and Metabolic (CVRM) diseases.

Thanks to a proven and rigorous selection process,

we are strategically positioned to develop the best projects from Europe’s top academic research centers such as Inserm in France.

Our Aim is to derisk up to 4 breakthrough therapeutic programs bringing them closer to the clinic and transition into a leading CVRM Biotech company